Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load

Molecular Therapy

Volumn 9, Issue 6, 2004, Pages 902-913

  Humeau, Laurent M ^a   Binder, Gwendolyn K ^a   Lu, Xiaobin ^a   Slepushkin, Vladimir ^a   Merling, Randall ^a   Echeagaray, Patricia ^a   Pereira, Mario ^a   Slepushkina, Tatiana ^a   Barnett, Scott ^b   Dropulic, Lesia K ^c   Carroll, Richard ^d   Levine, Bruce L ^d   June, Carl H ^d   Dropulic, Boro ^a,e  

^a VIRxSYS Corporation   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Division of Infectious Diseases   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Acquired immunodeficiency syndrome; CD4 positive T lymphocytes; Clinical trials; Gene therapy; Genetic vectors; HIV 1; Lentivirus; Viral RNA

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CD4 ANTIGEN; ENVELOPE PROTEIN; GREEN FLUORESCENT PROTEIN; LENTIVIRUS VECTOR; TRANSACTIVATOR PROTEIN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MODIFICATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEASIBILITY STUDY; FEMALE; GENE THERAPY; GENE TRANSFER; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; INHIBITION KINETICS; LONG TERMINAL REPEAT; LYMPHOCYTE COUNT; LYMPHOCYTE TRANSFER; MALE; MARKER GENE; PROMOTER REGION; T LYMPHOCYTE; TRANSACTIVATION; VESICULAR STOMATITIS VIRUS; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CULTURE; VIRUS INHIBITION; VIRUS LOAD; VIRUS REPLICATION; VIRUS TYPING;

ANTIGENS, SURFACE; ANTISENSE ELEMENTS (GENETICS); CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DOWN-REGULATION; GENE THERAPY; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; TRANSDUCTION, GENETIC; VIRAL LOAD; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS;

EID: 3042735441     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2004.03.005     Document Type: Article

References (41)

1. Chun T.W. et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection Nature 387 1997 183-188
2. + T cells Nat. Med. 9 2003 727-728
3. Vigouroux C. et al. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease Diabetes Metab. 25 1999 385-392
4. Behrens G.M.N. Stoll M. Schmidt R.E. Lipodystrophy in HIV infection. What is it, what causes it, and how can it be managed? Drug Saf. 23 2000 57-76
5. Powderly W.G. Long-term exposure to lifelong therapies J. Acquired Immune Defic. Syndr. 29S 2003 28-40
6. Max B. Sherer R. Management of the adverse effects of antiretroviral therapy and medication adherence Clin. Infect. Dis. 30S 2000 96-116
7. Lucas G.M. Chaisson R.E. Moore R.D. Highly active antiretroviral therapy in a large urban clinic: risk factor for virologic failure and adverse drug reactions Ann. Intern. Med. 131 1999 81-87
8. Nijuis M. Deeks S. Boucher C. Implications of antiretroviral resistance on viral fitness Curr. Opin. Infect. Dis. 14 2001 23-28
9. Tuner B.J. Adherence to antiretroviral therapy by human immunodeficiency virus-infected patients J. Infect. Dis. 185S 1993 145-151
10. 11th International Workshop for HIV Drug Resistance (2002). Rapid Report.
11. Little S.J. et al. Antiretroviral-drug resistance among patients recently infected with HIV N. Engl. J. Med. 347 2002 385-394
12. Lazzarin A. et al. TORO 2 Study Group Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia N. Engl. J. Med. 348 2003 2186-2195
13. Trono D. Feinberg M.B. Baltimore D. HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus Cell 59 1989 113-120
14. Sarver N. Rossi J. Gene therapy: a bold direction for HIV-1 treatment AIDS Res. Hum. Retroviruses 9 1993 483-487
15. Dropulic B. Jeang K.-T. Gene therapy for human immunodeficiency virus infection: genetic antiviral strategies and targets for intervention Hum. Gene Ther. 5 1994 927-939
16. Veres G. et al. Comparative analyses of intracellularly expressed antisense RNAs as inhibitors of human immunodeficiency virus type 1 J. Virol. 72 1998 1894-1901
17. Qin X.-F. An D.S. Chen I.S. Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral mediated delivery of small interfering RNA against CCR5 Proc. Natl. Acad. Sci. USA 100 2003 183-188
18. Dropulic B. Hermanokova M. Pitha P.M. A conditionally replicating HIV-1 vector interferes with wild type HIV-1 replication and spread Proc. Natl. Acad. Sci. USA 93 1996 11103-11108
19. Lu X. et al. Antisense-mediated inhibition of HIV replication using an HIV-1-based vector results in severely attenuated mutants incapable of developing resistance J. Virol. 2004 (in press)
20. Adachi A. et al. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone J. Virol. 59 1986 284-291
21. Lu X. et al. J. Gen. Med. 2004 (in press)
22. Ranga U. et al. Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals Proc. Natl. Acad. Sci. USA 95 1998 1202-1206
23. + T cells in human immunodeficiency virus-infected subjects Blood 96 2000 785-793
24. Walker R.E. et al. Long-term survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection Blood 96 2000 467-474
25. MacGregor R.R. Clinical protocol: a phase I open label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects Hum. Gene Ther. 12 2001 2028-2029
26. + T cells in the absence of exogenous feeder cells J. Immunol. 159 1997 5921-5930
27. Roos M.T.L. et al. Low T-cell responses to CD3 plus CD28 monoclonal antibodies are predictive of development of AIDS AIDS 12 1998 1745-1751
28. Hofmann B. et al. Lymphocyte transformation response to pokeweed mitogen as a predictive marker for development of AIDS and AIDS related symptoms in homosexual men with HIV antibodies Br. Med. J. 295 1987 293-296
29. Schellekens P.T. Roos M.T. De Wolf F. Lange J.M. Miedema F. Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus-1 (HIV-1) infected men J. Clin. Immunol. 10 1990 121-127
30. Benson R.E. Sanfridson A. Ottinger J.S. Doyle C. Cullen B.R. Downregulation of cell-surface CD4 expression by simian immunodeficiency virus nef prevents viral superinfection J. Exp. Med. 177 1993 1561-1566
31. Morner A. et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage J. Virol. 73 1999 2343-2349
32. Aiuti A. et al. Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement Nat. Med. 8 2002 423-425
33. Jensen M.E. van't Wout A.B. Predicting HIV-1 coreceptor usage with sequence analysis AIDS Rev. 5 2003 104-112
34. Simmonds P. Balfe P. Peutherer J.F. Ludlam C.A. Bishop J.O. Brown A.J. Human immunodeficiency virus-infected individuals contain provirus in small numbers of peripheral mononuclear cells and at low copy numbers J. Virol. 64 1990 864-872
35. Richard E. et al. A bicistronic SIN-lentiviral vector containing G156A MGMT allows selection and metabolic correction of hematopoietic protoporphyric cell lines J. Gene Med. 5 2003 737-747
36. Davis B. Humeau L. Dropulic B. In vivo selection for human and murine hematopoietic cells transduced with a therapeutic MGMT lentiviral vector that inhibits HIV replication Mol. Ther. 9 2004 160-172
37. + T cell proliferation in HIV-positive patients as a result of CD28 costimulation Science 272 1996 1939-1943
38. + T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection Nat. Med. 8 2002 47-53
39. Lu X. Welsh T.M. Peterlin B.M. The human immunodeficiency virus type 1 long terminal repeat specifies two different transcription complexes, only one of which is regulated by tat J. Virol. 67 1992 1752-1760
40. www.fda.gov/ohrms/dockets/ac/01/briefing/3794b3.htm
41. Slepushkin V. et al. Large-scale purification of a lentiviral vector by size exclusion chromatography or mustang Q ion exchange capsule Bioprocesses J. 2 2003 89-95